Recent advances of siRNA delivery by nanoparticles

Expert Opinion on Drug Delivery

Volumn 8, Issue 4, 2011, Pages 521-536

  Yuan, Xudong ^a   Naguib, Sandy ^a   Wu, Zhiqian ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Drug delivery; gene delivery; nanoparticle; non viral vector; RNA interference; siRNA

Indexed keywords

ALN VSP02; ARGINYLGLYCYLASPARTIC ACID; ATU 027; AZETIDINE; CALAA 01; CARBOSILANE; CHITOSAN; CISPLATIN; CYCLODEXTRIN; DENDRIMER; DEXTRAN; DOXORUBICIN; LAMIVUDINE; LIPOPLEX; LIPOSOME; LOCKED NUCLEIC ACID; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; PACLITAXEL; PDRIVE SH ANXA2 PLASMID DNA; PLASMID DNA; POLYCAPROLACTONE; POLYETHYLENEIMINE; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING LOCKED NUCLEIC ACID; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ANTIVIRAL ACTIVITY; CANCER GENE THERAPY; CANCER INHIBITION; COLORECTAL CANCER; CYTOKINE RELEASE; DOSE RESPONSE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG TARGETING; ENDOSOME; FAMILIAL COLON POLYPOSIS; FLUORESCENCE MICROSCOPY; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MUCOADHESION; NANOENCAPSULATION; NASOPHARYNX TUMOR; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERIZATION; PROSTATE TUMOR; REVIEW; RNA BINDING; RNA DEGRADATION; RNA INTERFERENCE; RNA STABILITY; SOLID TUMOR; STATIC ELECTRICITY; THYROID PAPILLARY CARCINOMA; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; HUMANS; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 79952939225     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.559223     Document Type: Review

References (100)

1. Leung RK, Whittaker PA. RNA interference: From gene silencing to gene-specific therapeutics. Pharmacol Ther 2005;8(2):222-39. This is a review paper discussing the mechanism of RNAi and the potential of siRNA being used as gene-specific therapeutics. (Pubitemid 40910042)
2. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-38
3. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: Recent progress. BioDrugs 2010;24(3):195-205. This is a good review paper about the recent progress of in vivo delivery of siRNA therapeutics.
4. Hart SL. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol Toxicol 2010;26(1):69-81
5. Jin S, Leach JC, Ye K. Nanoparticle-mediated gene delivery. Methods Mol Biol 2009;544:547-57
6. Pathak A, Patnaik S, Gupta KC. Recent trends in non-viral vector-mediated gene delivery. Biotechnol J 2009;4(11):1559-72
7. Wang SL, Yao HH, Qin ZH. Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther 2009;9(11):1357-68. This is a review paper regarding possible utilization of shRNA for long-term gene silencing for cancer gene therapy.
8. Zhou J, Rossi JJ. The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem 2009;9(12):1144-57
9. Singh N, Agrawal A, Leung AK, et al. Effect of nanoparticle conjugation on gene silencing by RNA interference. J Am Chem Soc 2010;132(24):8241-3
10. Shmueli RB, Anderson DG, Green JJ. Electrostatic surface modifications to improve gene delivery. Expert Opin Drug Deliv 2010;7(4):535-50
11. de Martimprey H, Vauthier C, Malvy C, et al. Polymer nanocarriers for the delivery of small fragments of nucleic acids: Oligonucleotides and siRNA. Eur J Pharm Biopharm 2009;71(3):490-504
12. Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010;2(3):305-15
13. Yu X, Zhang Y, Chen C, et al. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta 2010;1805(1):97-104
14. Blagbrough IS, Zara C. Animal models for target diseases in gene therapy-using DNA and siRNA delivery strategies. Pharm Res 2009;26(1):1-18. This paper introduces some animal models for target diseases by using siRNA therapeutics.
15. Yuan X, Li L, Rathinavelu A, et al. SiRNA drug delivery by biodegradable polymeric nanoparticles. J Nanosci Nanotechnol 2006;6(9-10):2821-8. This is one of earliest papers reporting about siRNA silencing by polymeric nanoparticles. (Pubitemid 44579952)
16. Cun D, Foged C, Yang M, et al. Preparation and characterization of poly (DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm 2010;390(1):70-5
17. Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010;31(2):358-65
18. Braden AR, Kafka MT, Cunningham L, et al. Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth. J Nanosci Nanotechnol 2010;9(5):2856-65
19. Luo G, Jin C, Long J, et al. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer Biol Ther 2009;8(7):594-8
20. Jensen DM, Cun D, Maltesen MJ, et al. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release 2010;142(1):138-45
21. Andersen MO, Lichawska A, Arpanaei A, et al. Surface functionalisation of PLGA nanoparticles for gene silencing. Biomaterials 2010;31(21):5671-7. This paper reports on the strategies to functionalize the PLGA nanoparticles for improved gene silencing by siRNA.
22. Yuan X, Shah BA, Kotadia NK, et al. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 2010;27(7):1285-95. This paper reports the cationic chitosan-modified PLGA nanoparticles for improved delivery and enhanced gene silencing by siRNA.
23. Tahara K, Yamamoto H, Hirashima N, et al. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm 2010;74(3):421-6
24. Qiu XF, Dong NG, Sun ZQ, et al. Controlled release of siRNA nanoparticles loaded in a novel external stent prepared by emulsion electrospinning attenuates neointima hyperplasia in vein grafts. Zhonghua Yi Xue Za Zhi 2009;89(41):2938-42
25. Liu X. Chitosan-siRNA complex nanoparticles for gene silencing. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2010;27(1):97-101
26. Tan ML, Choong PF, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2010;61(1):3-12
27. Wang SL, Yao HH, Guo LL, et al. Selection of optimal sites for TGFB1 gene silencing by chitosan-TPP nanoparticle-mediated delivery of shRNA. Cancer Genet Cytogenet 2009;190(1):8-14
28. Ji AM, Su D, Che O, et al. Functional gene silencing mediated by chitosan/ siRNA nanocomplexes. Nanotechnology 2009;20(40):405103
29. Malhotra M, Kulamarva A, Sebak S, et al. Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Dev Ind Pharm 2009;35(6):719-26
30. Cai YQ, Chen SR, Han HD, et al. Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem 2009;111(4):1000-10
31. de Martimprey H, Bertrand JR, Malvy C, et al. New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm Res 2010;27(3):498-509
32. Hee-Dong H, Mangala LS, Lee JW, et al. Targeted gene silencing using rgd-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22
33. Andersen MO, Howard KA, Kjems J. RNAi using a chitosan/siRNA nanoparticle system: In vitro and in vivo applications. Methods Mol Biol 2009;555:77-86
34. Ghosn B, Singh A, Li M, et al. Efficient gene silencing in lungs and liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. Oligonucleotides 2010;20(3):163-72
35. Glud SZ, Bramsen JB, Dagnaes-Hansen F, et al. Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 2010;19(2):163-8
36. Gao S, Dagnaes-Hansen F, Nielsen EJ, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 2010;17(7):1225-33
37. Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2010;17(1):162-8
38. Dehousse V, Garbacki N, Jaspart S, et al. Comparison of chitosan/siRNA and trimethylchitosan/siRNA complexes behaviour in vitro. Int J Biol Macromol 2010;46(3):342-9
39. Dehousse V, Garbacki N, Colige A, et al. Development of pH-responsive nanocarriers using trimethylchitosans and methacrylic acid copolymer for siRNA delivery. Biomaterials 2010;31(7):1839-49
40. Lee DW, Yun KS, Ban HS, et al. Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release 2009;139(2):146-52
41. Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5(5):e10764
42. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 2009;6(3):659-68. This paper reports the fist targeted delivery of siRNA in humans by cyclodextrin-based nanoparticles.
43. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464(7291):1067-70. This paper reports the first targeted delivery of siRNA in humans from systemically administered cyclodextrin-based and targeted nanoparticles.
44. Howard KA. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv Drug Deliv Rev 2009;61(9):710-20. This paper reviews polycation-based nanoparticles for siRNA delivery.
45. Buyens K, Meyer M, Wagner E, et al. Monitoring the disassembly of siRNA polyplexes in serum is crucial for predicting their biological efficacy. J Control Release 2010;141(1):38-41
46. Cubillos-Ruiz JR, Engle X, Scarlett UK, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009;119(8):2231-44. This paper reports the use of siRNA-loaded nanoparticles for cancer immunotherapy.
47. Swami A, Goyal R, Tripathi SK, et al. Effect of homobifunctional crosslinkers on nucleic acids delivery ability of PEI nanoparticles. Int J Pharm 2009;374(1-2):125-38
48. Beyerle A, Hobel S, Czubayko F, et al. In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicol In Vitro 2009;23(3):500-8
49. Alshamsan A, Hamdy S, Samuel J, et al. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 2010;31(6):1420-8
50. Nimesh S, Chandra R. Polyethylenimine nanoparticles as an efficient in vitro siRNA delivery system. Eur J Pharm Biopharm 2009;73(1):43-9
51. Patnaik S, Arif M, Pathak A, et al. PEI-alginate nanocomposites: Efficient non-viral vectors for nucleic acids. Int J Pharm 2010;385(1-2):194-202
52. Patnaik S, Arif M, Pathak A, et al. Cross-linked polyethylenimine- hexametaphosphate nanoparticles to deliver nucleic acids therapeutics. Nanomedicine 2010;6(2):344-54
53. Philipp A, Zhao X, Tarcha P, et al. Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. Bioconjug Chem 2009;20(11):2055-61
54. Kim SH, Ou M, Bull DA, et al. Reductive degradation behavior of bioreducible poly(disulfide amine) for enhancing siRNA efficiency. Macromol Biosci 2010;10(8):898-905
55. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 2009;367(1-2):195-203
56. Katas H, Cevher E, Alpar HO. Preparation of polyethyleneimine incorporated poly(D,L-lactide-coglycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Int J Pharm 2009;369(1-2):144-54
57. Jere D, Arote R, Jiang HL, et al. Biodegradable nano-polymeric system for efficient Akt1 siRNA delivery. J Nanosci Nanotechnol 2010;10(5):3366-9
58. Yadav S, van Vlerken LE, Little SR, et al. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 2009;63(4):711-22
59. Wu Y, Wang W, Chen Y, et al. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine 2010;5:129-36
60. Tseng YC, Huang L. Self-assembled lipid nanomedicines for siRNA tumor targeting. J Biomed Nanotechnol 2009;5(4):351-63
61. Tao W, Davide JP, Cai M, et al. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther 2010;18(9):1657-66
62. Hattori Y, Hakoshima M, Koga K, et al. Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel. Int J Oncol 2010;36(4):1039-46
63. Hattori Y. Development of non-viral vector for cancer gene therapy. Yakugaku Zasshi 2010;130(7):917-23
64. Hamelers IH, Staffhorst RW, Voortman J, et al. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. Clin Cancer Res 2009;15(4):1259-68
65. Akita H, Kogure K, Moriguchi R, et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. J Control Release 2010;143(3):311-17
66. Sakurai Y, Hatakeyama H, Akita H, et al. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. Biol Pharm Bull 2009;32(5):928-32
67. Islam RU, Hean J, van Otterlo WA, et al. Efficient nucleic acid transduction with lipoplexes containing novel piperazine- and polyamine-conjugated cholesterol derivatives. Bioorg Med Chem Lett 2009;19(1):100-3
68. Ghonaim HM, Li S, Blagbrough IS. Very long chain N4, N9-diacyl spermines: Non-viral lipopolyamine vectors for efficient plasmid DNA and siRNA delivery. Pharm Res 2009;26(1):19-31
69. Ghonaim HM, Li S, Blagbrough IS. N1, N12-Diacyl spermines: SAR studies on non-viral lipopolyamine vectors for plasmid DNA and siRNA formulation. Pharm Res 2010;27(1):17-29
70. Klein E, Leborgne C, Ciobanu M, et al. Nucleic acid transfer with hemifluorinated polycationic lipids. Biomaterials 2010;31(17):4781-8
71. Nguyen DN, Chen SC, Lu J, et al. Drug delivery-mediated control of RNA immunostimulation. Mol Ther 2009;17(9):1555-62
72. Mevel M, Kamaly N, Carmona S, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release 2010;143(2):222-32
73. Midoux P, Pichon C, Yaouanc JJ, et al. Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009;157(2):166-78
74. Damen M, Aarbiou J, van Dongen SF, et al. Delivery of DNA and siRNA by novel gemini-like amphiphilic peptides. J Control Release 2010;145(1):33-9
75. Schroeder A, Levins CG, Cortez C, et al. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2010;267(1):9-21
76. Huang Z, King MR. An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation. Gene Ther 2009;16(10):1271-82
77. Zhang C, Newsome JT, Mewani R, et al. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol 2009;480:65-83
78. Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 2010;267(1):44-53. This paper reviews the use of nanomedicine for the delivery of siRNA to cancer.
79. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer. Biochim Biophys Acta 2009;1788(10):2259-66
80. Chen Y, Bathula SR, Li J, et al. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010;285(29):22639-50
81. Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18(9):1650-6
82. Yagi N, Manabe I, Tottori T, et al. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res 2009;69(16):6531-8
83. Kim SI, Shin D, Lee H, et al. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol 2009;50(3):479-88
84. Woodrow KA, Cu Y, Booth CJ, et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009;8(6):526-33
85. Ravina M, Paolicelli P, Seijo B, et al. Knocking down gene expression with dendritic vectors. Mini Rev Med Chem 2010;10(1):73-86
86. Pavan GM, Albertazzi L, Danani A. Ability to adapt: Different generations of PAMAM dendrimers show different behaviors in binding siRNA. J Phys Chem B 2010;114(8):2667-75. This paper discusses interaction of siRNA with different generations of PAMAM dendrimers.
87. Minko T, Patil ML, Zhang M, et al. LHRH-targeted nanoparticles for cancer therapeutics. Methods Mol Biol 2010;624:281-94
88. Patil ML, Zhang M, Taratula O, et al. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: Effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009;10(2):258-66
89. Waite CL, Sparks SM, Uhrich KE, et al. Acetylation of PAMAM dendrimers for cellular delivery of siRNA. BMC Biotechnol 2009;9:38
90. Chen WT, Thirumalai D, Shih TT, et al. Dynamic contrast-enhanced folate-receptor-targeted MR imaging using a Gd-loaded PEG-dendrimer-folate conjugate in a mouse xenograft tumor model. Mol Imaging Biol 2010;12(2):145-54
91. Perez AP, Romero EL, Morilla MJ. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int J Pharm 2009;380(1-2):189-200
92. Liu XX, Rocchi P, Qu FQ, et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem 2009;4(8):1302-10
93. Taratula O, Garbuzenko OB, Kirkpatrick P, et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009;140(3):284-93
94. Posadas I, Lopez-Hernandez B, Clemente MI, et al. Highly efficient transfection of rat cortical neurons using carbosilane dendrimers unveils a neuroprotective role for HIF-1alpha in early chemical hypoxia-mediated neurotoxicity. Pharm Res 2009;26(5):1181-91
95. Gras R, Almonacid L, Ortega P, et al. Changes in gene expression pattern of human primary macrophages induced by carbosilane dendrimer 2G-NN16. Pharm Res 2009;26(3):577-86
96. Agrawal A, Min DH, Singh N, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano 2009;3(9):2495-504
97. Han L, Zhang A, Wang H, et al. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 2010;21(4):417-26
98. Roth L. First evidence of RNA interference mechanism induced in human: Getting closer to a cure? Cell Adh Migr 2011 [Epub ahead of print] This paper discusses the significance of the first RNAi mechanism induced in humans.
99. Watts JK, Corey DR. Clinical status of duplex RNA. Bioorg Med Chem Lett 2010;20(11):3203-7
100. Brower V. RNA interference advances to early-stage clinical trials. J Natl Cancer Inst 2010;102(19):1459-61. This paper reports the current status of clinical trials of several siRNA products.